Filing Flows › Ideaya Biosciences (IDYA) › Q4 2025
Ideaya Biosciences (IDYA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 17, 2026
Ideaya Biosciences (IDYA) reported revenue of $10.9M for the fourth quarter 2025 (Q4 2025), +55% from a year earlier and -95% from the quarter before. Operating margin was -869.5%, net loss $83.3M (765.7% of revenue).
Ideaya Biosciences, Q4 2025: revenue $10.9M (+55% year over year), operating margin -869.5%, net loss $83.3M, operating cash flow −$90.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.9M | -95% | +55% |
| Operating profit | −$94.6M | -187% | — |
| Net earnings | −$83.3M | -170% | — |
| Operating cash flow | −$90.5M | -164% | — |
What changed
Revenue was $10.9M in Q4 2025, up 55% year over year and down 95% from the previous quarter.
Operating costs exceeded revenue by $94.6M, an operating margin of -869.5%. Total costs fell 30% while revenue rose 55%. The fastest-growing cost line was General & admin (+72%). The quarter ended with a net loss of $83.3M, after a profit of $119.2M the previous quarter.
Operating cash flow was −$90.5M. Non-cash charges added back $721K of depreciation and amortization and $11.8M of share-based compensation. Working capital and other items used $19.7M. Capital expenditures of $333K exceeded it, leaving free cash flow of −$90.8M.
Questions
What was Ideaya Biosciences' revenue in the fourth quarter 2025?
Ideaya Biosciences (IDYA) reported revenue of $10.9M for the fourth quarter 2025 (Q4 2025), +55% from a year earlier and -95% from the quarter before.
Was Ideaya Biosciences profitable in the fourth quarter 2025?
Operating loss was $94.6M (-869.5% of revenue) and net loss $83.3M.
Source: Ideaya Biosciences 10-K on SEC EDGAR.